Sonnet BioTherapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) € in Millions	1 Months Ended			3 Months Ended		6 Months Ended
	Aug. 31, 2024	Apr. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2025 EUR (€)	Apr. 30, 2023 USD ($)	Jan. 31, 2019 USD ($)	Jul. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Payments to Acquire in Process Research and Development						$ 12,000
Discovery Collaboration Agreements [Member]
Loss Contingencies [Line Items]
License fees				$ 0	$ 0	0	0
Discovery Collaboration Agreements [Member] \| XOMA [Member]
Loss Contingencies [Line Items]
MilestonePayments											$ 3,800,000
Discovery Collaboration Agreements [Member] \| XOMA [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees		$ 500,000		0	0	0	0
Alkem Agreement [ Member]
Loss Contingencies [Line Items]
MilestonePayments				1,000,000.0		1,000,000.0
License fees						100,000
Cellca Agreement [Member]
Loss Contingencies [Line Items]
MilestonePayments				600,000		$ 600,000
Description of milestone payments						The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.
Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
MilestonePayments										$ 700,000
Payment for annual license fee obligation				600,000		$ 600,000
Cellca Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000		100,000
Cellca Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees				0	0	0	0
Commercial product license fee payment obligation		$ 100,000
The Brink Agreement [Member]
Loss Contingencies [Line Items]
License fees				0	0	12,000	12,000
Commercial product license fee payment obligation				100,000		100,000
Annual license fee									$ 12,000
Cell line storage fee						12,000
The Brink Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
Development license fee				100,000		100,000
InvivoGen Agreement [Member]
Loss Contingencies [Line Items]
License fees				0	0	0	0
Payment for annual license fee obligation				100,000		100,000		€ 0.1
SOC Agreement [Member]
Loss Contingencies [Line Items]
Agreements description	Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership.
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member]
Loss Contingencies [Line Items]
MilestonePayments			$ 1,000,000.0	0	0	0	0
License fees				$ 0	$ 0	$ 0
Payments to Acquire in Process Research and Development			100,000
Evaluation milestone recognized			$ 300,000
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
License fees							$ 0